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1. 
PRODUCTION OF HIGH LEVELS OF 
TRANSGENCFACTORIX WITHOUT GENE 
RESCUE, AND ITS THERAPEUTIC USES 
This application is a continuation under 37 C.F.R.S 1.53(b) 
of patent application Ser. No. 10/471,492 filed on Feb. 12, 
2004, now abandoned which is a 371 of PCT/US02/07532, 
filed Mar. 11, 2002, which claims benefit of U.S. Provisional 
Application No. 60/274,983 filed Mar. 12, 2001, each of 
which are incorporated herein by reference in their entirety. 
FIELD OF THE INVENTION 
The invention provides, among other things, a system for 
producing transgenic proteins, compositions comprising 
transgenic proteins, transgenic organisms for making pro 
teins, for modifying transgenic proteins in vivo. Illustrative 
embodiments of the invention particularly provide transgenic 
animals that express an exogenous gene for vitamin K-depen 
dent proteins, protease inhibitors, blood clotting proteins and 
mammalian relaxins. In a highly particular illustrative 
embodiment in this regard the invention provides transgenic 
female pigs that express these same proteins in their milk in a 
temporally controlled manner during lactation using a multi 
gene inducible system. In this regard, the invention relates 
particularly to female pigs having stably incorporated in their 
genomes non-endogenous DNA comprising a region that 
encodes these same proteins operably linked to a multi-gene 
system containing at least two different promoters in separate 
DNA constructs, where one of these promoters is a non 
mammary gland specific promoter. Further in this regard the 
invention relates to the mill containing these same proteins 
and corresponding compositions derived from the milk. And 
it also relates to, among other things, uses of these proteins in 
wellness and therapeutic applications. 
BACKGROUND 
The concept of producing important pharmaceutical and 
nutriceutical proteins in transgenic animals is now firmly 
established (Van Cott, K. E. and Velander, W. H., Exp. Opin. 
Invest. Drugs, 7(10): 1683-1690 (1998)), with three potential 
products, alpha-1 antitrypsin, antithrombin III and alpha glu 
cosidase in the late stages of clinical trials. These proteins, 
and nearly all other transgenic polypeptides being developed 
commercially, were produced from a single DNA construct 
designed to produce a single polypeptide. In general terms, 
this “classical design incorporates three distinct regions of 
DNA, which are all joined or operably linked in one contigu 
ous Strand. 
The first region of DNA is a tissue specific promoter, in the 
above mentioned examples a milk protein promoter, which 
directs expression of the gene to a target organ, the mammary 
gland, which is regulated by lactogenic hormones, growth 
factors, cell-cell and cell-substratum interactions. The second 
region of DNA is the coding region, which may consist of 
complimentary DNA (cDNA, containing no introns), 
genomic DNA (gDNA) or a combination of both in a format 
called a mini-gene. It is important to note that cDNAs, and 
perhaps also minigenes, have a silencing effect (failure to 
express or poor expression levels) on adjacent transgenes 
(Clark, A. J., et al., NAR, 25 (5), 1009-1014, 1997). There 
fore, a method of overcoming this silencing effect using non 
genomic DNA sequences is highly desirable. The coding 
region contains the information needed to produce a specific 
protein, including any processing and secretory signals. The 
third region, the 3' region, contains further regulatory 
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sequences and may influence the quantity of polypeptide that 
is produced from that construct. Non-genomic DNA 
sequences are inherently smaller than g|DNA sequences and 
are therefore, much easier to manipulate in classical trans 
gene formats. 
Although this classical design has been Successful in pro 
ducing commercially viable quantities of certain proteins, 
there are two areas in which this system is not optimal. First, 
it is generally accepted that using cDNAS or minigenes in a 
classically designed construct, is less efficient for protein 
production than using a corresponding gCNA coding region. 
Indeed, this is such a problem that methods have been devel 
oped to address this issue (Clark, A. J. et al. Biotechnology 
10, 1450-1454, 1992). Whilst these methods can improve the 
efficiency and level of expression of cDNAs and minigenes to 
Some extent, they do not improve expression to the same level 
as is typically obtained using gCNA. A higher level would be 
ideal for commercial protein production. 
The second area in which the classical single gene DNA 
construct design is Suboptimal is in the production of highly 
biologically active proteins in transgenic animals. Proteins 
with an extremely high biological activity can be detrimental 
to the transgenic animal, even if circulatory levels (or other 
systemic levels) are low (Castro, F. O., et al., Selection of 
Genes for Expression in Milk: The Case of the Human EPO 
Gene, in Mammary Gland Transgenesis. Therapeutic Protein 
Production. Castro and Janne (eds.) Springer-Verlag Berlin 
N.Y., 91-106, 1998). This can be due in large part to either 
ectopic expression (expression of the transgene in organs 
other than the targeted one) or leakage of the protein product 
into the blood from the target organ. If the protein product is 
highly biologically active, expression ideally must be strictly 
controlled so that the animal is exposed to the product for a 
short time only, thus reducing the chance of any lasting det 
rimental effects. This requires an expression system that can 
be turned on and off very rapidly and precisely. 
Regulation of Promoters 
The expression of many genes is controlled at the level of 
transcription, when the DNA sequences are transcribed into 
RNA, prior to being translated into protein (Latchman, D. S., 
Eukaryotic Transcription Factors, Academic Press, 1998). 
The DNA sequence element that controls transcription is the 
promoter. This generally contains a small core region, which 
is capable of directing constitutive or basal levels of transcrip 
tion, and upstream response elements that control spatial and 
temporal regulation of transcription. These DNA sequences 
include two types of elements, those which are involved in the 
basic process of transcription and are found in many genes 
exhibiting distinct patterns of regulation, and those found 
only in genes transcribed in a particular tissue or in response 
to a specific signal. The latter elements likely produce this 
specific expression pattern. They are binding sites for a wide 
range of different cellular proteins (transcription factors) 
whose levels fluctuate in response to stimuli from external or 
internal Sources, Gene expression in a given tissue may be 
stimulated or inhibited depending on the type and amount of 
transcription factors that are present in that tissue at any time. 
Many transcription factors or other proteins that enable tran 
Scription factor pathways are largely uncharacterized from 
the perspective of an exact biochemical analysis, which 
details their conformationally-dependent interactions with 
DNA. Overall, the regulation of expression at the DNA level, 
is a function of which regulatory elements (binding sites) are 
present in the promoter and how the cell or tissue responds to 
its environment by changing the relative levels of the different 
DNA binding transcription factors in the cell. 
US 7,888,321 B2 
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Another mechanism involved in the precise control of gene 
expression is transcriptional repression (Maldonado, E., et al. 
Cell, 99(5), 455-458, 1999). Transcriptional repressor pro 
teins associate with their target genes either directly through 
a DNA-binding domain or indirectly by interacting with other 
DNA-bound proteins. The repressor protein can inhibit tran 
Scription by masking a transcriptional activation domain, 
blocking the interaction of an activator with other transcrip 
tion components or by displacing an activator from the DNA. 
Milk protein genes are characterized by a strict tissue spe 
cific expression and regulation during the process of func 
tional differentiation. They are coordinately expressed in 
response to various developmental signals, such as changing 
levels of lactogenic hormones (prolactin, insulin, glucocorti 
coids, progesterone), local levels of certain growth factors 
(EGF), cell-cell interactions and interactions with extra-cel 
lular matrix (ECM) components (Rijnkels, M. and Pieper, F. 
R., Casein Gene-Based Mammary Gland-Specific Transgene 
Expression, in Mammary Gland Transgenesis. Therapeutic 
Protein Production. Castro and Janne (eds.) Springer-Verlag, 
Berlin, N.Y., 41-64, 1998). 
Lactogenic hormones activate latent transcription factors 
in the cytoplasm of mammary epithelial cells. The steroid 
hormones progesterone, estrogen, and glucocorticoid regu 
late the transcription of target genes by binding to specific 
intracellular receptors. Some models purport that binding of 
the hormone with its receptor changes the receptors confor 
mation from a physiologically inactive form to a form which 
is active and capable of dimerization. The active receptors are 
then capable of binding specific DNA sites in the regulatory 
region of the target gene promoters, stimulating gene tran 
scription and thus, protein synthesis. Steroid receptors belong 
to a Superfamily of ligand-inducible transcription factors and 
it has been well documented that these are modular proteins 
organized into structurally and functionally defined domains. 
It has also been shown that these domains can be rearranged 
as independent cassettes within their own molecules or as 
hybrid molecules with domains from other regulatory pep 
tides. Interestingly, the transactivation domains of the gluco 
corticoid receptor can be duplicated in tandem and show 
positional independence in a “super receptor with 3-4 times 
the activity of the wild type protein. (Hollenberg, S. M. and 
Evans, R. M., Cell, 55, 899-906, 1988: Fuller, P.J., FASEB.J., 
5,3092-3099, 1991; U.S. Pat. No. 5,364,791; U.S. Pat. No. 
5,935,934: Whitfield, G. K., et al., J. Cell. Biochem., suppl. 
32-33, 110-122, 1999: Braselmann, S., etal, PNAS,90, 1657 
1666, 1993). The structure and function of the steroid recep 
tor superfamily is well conserved. Generally there are three 
main domains and several Sub-domains or regions. The NH2 
terminal domain is the least conserved in size and sequence 
and contains one of the two, transactivation sequences of the 
receptor. The central DNA binding domain of about 70 amino 
acids is highly conserved, as is the COOH-terminal ligand 
binding domain. This latter domain also contains Sub-do 
mains responsible for dimerization, heat shock protein (lisp) 
90 binding, nuclear localization and transactivation. 
Prolactin plays the essential role in milk protein gene 
expression and exerts its effect through binding to the extra 
cellular domain of the prolactin receptor and through receptor 
dimerization. This activates a protein tyrosine kinase (JAK2) 
which is non-covalently associated with the cytoplasmic 
domain of the prolactin receptor (Gouilleux, F., et al., EMBO 
J., 13(18), 4361-4369, 1994: Imada, K. and Leonard, W.J., 
Mol. Immunol. 37 (1-2), 1-11, 2000). The activated JAK2 
phosphorylates the signal transducer and transcription acti 
vator, Stat 5, causing it to dimerize and Subsequently, trans 
locate to the nucleus. Once in the nucleus, Stats specifically 
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binds to sequence elements in the promoter regions of milk 
protein genes (Liu, X., et al., PNAS, 92, 8831-8835, 1995: 
Cella, N., et al. Mol. Cell. Biol., 18(4), 1783-1792, 1998: 
Mayr, S., et al., Eur. J. Biochem., 258(2), 784-793, 1998). In 
an analysis of 28 milk protein gene promoters (Malewski, T., 
BioSystems, 45,29-44, 1998) there were 4 transcription fac 
tor binding sites that were present in every promoter, C/EBP. 
CTF/NF1 MAF and MGF (Stat5). Although steroid hormone 
receptors and Stat factors comprise two distinct families of 
inducible transcription factors their basic structure is similar. 
Stat proteins are modular with an amino terminus that regu 
lates nuclear translocation and mediates the interaction 
between Stat dimers (Callus, B. A. and Mathey-Prevot, B., J. 
Biol. Chem., 275(22), 16954-16962, 2000). There is a central 
DNA binding domain and a carboxy terminal region, which 
contains the phosphorylation site and a transactivation 
domain. 
Egg white genes seem to be regulated in a similarly com 
plex manner. It is known that the progesterone-dependent 
activation of the egg white genes in the chicken oviduct is 
mediated through the progesterone receptor (Dobson, A. D. 
W., et al., J. Biol. Chem., 264(7), 4207-4211, 1989). In addi 
tion, the chicken ovalbumin upstream promoter-transcription 
factor (COUP-TF) is a high affinity and specific DNA binding 
protein, which interacts as a dimer with the distal promoter 
sequence of the ovalbumin gene and promotes initiation of 
transcription of this gene by RNA polymerase (O'Malley, B. 
W. and Tsai, M-J., Biol. Reprod., 46,163-167, 1992). COUP 
TFs are orphan members (no binding ligand has as yet been 
determined for these receptors) of the nuclear receptor super 
family, and have been shown to play a key role in the regula 
tion of organogenesis, neurogenesis, metabolic enzyme pro 
duction and cellular differentiation during embryogenic 
development, via transcriptional repression and activation 
(Sugiyama, T., et al., J. Biol. Chem..., 275(5), 3446-3454, 
2000). 
A protein expression method based on the inducible Tet 
repressor system has been developed (Furth, P. A., et al. 
PNAS, 91, 9302-9306, 1994), but the levels of basal expres 
sion without induction are too high to be useful in transgenic 
animals (Soulier S. et al., Eur. J. Biochem. 260, 533-539, 
1999). Another inducible system based on the use of the 
ecdysone receptor has been reported (No, D., et al., PNAS, 93, 
3346-3351, 1996: PCT 97/38117, PCT 99/58.155) and has 
recently given encouraging results in transgenic mice (Al 
banese, C. etal, FASEB.J., 14,877-884, 2000). However, this 
system required the delivery of an exogenous ligand to the 
mice for the full lactation period. Such a ligand would be 
costly and difficult to procure for regular administration in a 
production environment. 
A new multi-gene system for protein production in trans 
genic animals would improve commercial levels of produc 
tion from cDNA constructs by amplifying specifically tai 
lored transcription factors which need not naturally occur in 
the tissue targeted for expression, but would be transgenically 
expressed specifically in that tissue. Unlike classical gene 
expression formats for recombinant proteins, the tissue spe 
cific promoter would not be linked to the protein to be 
expressed, but would be used to drive expression of transcrip 
tion factors which do not have a signal sequence and so are not 
secreted. In addition, the added control that a doubly induc 
ible multi-gene system would provide, which is inexpensive 
and easily applied, could enable the production of highly 
biologically active proteins in transgenic animals in a pulsa 
tile fashion so as to avoid longterm detrimental effects. 
US 7,888,321 B2 
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Proteins for Transgenic Production 
A multi-gene system, as described below, can be used to 
direct expression of any protein, particularly any secreted 
protein, which can be expressed in a transgenic organism in 
useful quantities, either for research or commercial develop 
ment. Particular proteins of interest with respect to produc 
tion by multi-gene expression systems include relaxin and 
other hormones with cross-species activity Such as growth 
factors, erythropoitin (EPO) and other blood cell growth 
stimulating factors. For these proteins, the expression may be 
problematic in terms of harming the host animal as is known 
to happen when EPO is expressed for an extended period of 
time. It is noted that tissue specific expression of transgenesis 
not an absolute phenomenon and promiscuous expression or 
systemic transport of the expressed recombinant protein 
within the animal almost always occurs with any expression 
system in any animal, albeit at very low levels. However, even 
at low levels of expression of EPO, when the EPO is 
expressed over an extended period of time, the hematocrit of 
the host animal can rise to a fatal level. Thus a temporal 
control which can enable pulse expression using an external 
inducer molecule could overcome the problems of continu 
ous and extended expression (ie., as could occur if expression 
occurs over an entire lactation period). Pulse or truncated 
expression would be useful in preventing an adverse, sys 
temic physiologic effect by recombinant molecules like EPO, 
which can cause these effects at very low levels. 
Relaxin is widely known as a hormone of pregnancy and 
parturition and typically circulates at less than 50 pg/ml in the 
blood of women. However, it is now emerging that the peptide 
has a far wider biological function than was at first thought. 
There are receptor sites for relaxin in striated muscle, smooth 
muscle, cardiac muscle, connective tissue, the autonomic and 
the central nervous systems. Human relaxin has been dem 
onstrated to inhibit excessive connective tissue build-up and 
is in Phase II trials for the treatment of Scleroderma. Porcine 
relaxin was available commercially in the 1950-60s and was 
used extensively for Such conditions as cervical ripening, 
scleroderma, premature labour, PMS, decubital ulcers and 
glaucoma. Relaxin is known to adversely affect the lactation 
of different mammalian species but does not seem to affect 
the pig in a similar manner. Therefore, the pig is perfectly 
suited for production of relaxin in milk. 
Other examples of proteins which it would be desirable to 
produce in transgenic organisms, are proteins that are pro 
tease inhibitors. Some examples of protease inhibitors are 
Alpha 1-antitrypsin, Alpha 2 Macroglobulin, and serum leu 
kocyte protease inhibitor. These proteins are serine protease 
inhibitors that show antiviral, non-steroidal anti-inflamma 
tory and wound healing properties. These proteins are useful 
in Veterinary, cosmetic and nutriceutical applications. 
Alpha 1-antitrypsin (AAT) is a naturally occurring glyco 
protein produced by the liver. Improperly glycosylated 
recombinant AAT Such as made by yeast, does not have a 
sufficient circulation half-life to be used as a parenterally 
administered therapeutic. Congenital deficiency results in the 
condition emphysema and in 1985 Bayer Pharmaceuticals 
began marketing a plasma derived AAT product, Prolastin. 
Unfortunately, due to shortages of Asafe(a) plasma and fre 
quent recalls, supplies of Prolastin are often very limited. 
AAT has also been used to treat psoriasis, atopic dermatitis, 
ear inflammation, cystic fibrosis and emphysema, and to 
assist in wound healing. It has been estimated that over 10 
million people in the US alone may benefit from AAT thera 
pies. 
Alpha 2 macroglobulin (A2M) is a very large, complex 
glycoprotein with a published cDNA sequence containing 
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1451 amino acids. The mature protein is a tetrameric mol 
ecule composed of four 180 kDa subunits and thus has a 
molecular weight which is over 720 kDa. Its complexity 
makes it most Suited for production in mammalian systems 
but few mammalian systems will likely make A2M at com 
mercially viable levels. A2M is indicated for treatment of 
asthma, bronchial inflammation and eczema and acts as a 
protease inhibitor to both endogenous and exogenous pro 
teases that cause inflammation. A2M is necessarily more 
potent than alpha 1-antitrypsin due to its irreversible binding 
of target proteases. A2M is also useful in inhibiting proteases 
frequently found in (thermal) burn wounds from yeast and 
other infections. The high specific activity of these types of 
proteases allows for Smaller doses during treatment. Thus, 
A2M-s complexity and specific activity make it ideally 
Suited for production in transgenic pig mammary glands. 
Vitamin K-Dependent Proteins 
Vitamin K-dependent (VKD) proteins such as those pro 
teins associated with haemostasis have complex functions 
which are largely directed by their primary amino acid struc 
ture. In particular, the post-translational modification of 
glutamic acids in the amino terminal portion of these mol 
ecules is essential for proper biological activity. This includes 
biological activity of both pro-coagulation and anti-coagula 
tion. This particular domain found in VKD-proteins is called 
the 'gla domain’. For example, the Gla domain is an essential 
recognition sequence in tissue factor (TF) mediated pro-co 
agulation pathways. The anti-coagulation of this pathway 
depends upon the lipoprotein-associated coagulation inhibi 
tor, termed LACI, which is a non-VKD protein. LACI forms 
a complex with the Gla domain of factor Xa, factor VIIa, and 
TF. Specifically, the Gla domain of factor Xa (FXa) is needed 
for this procoagulation inhibitory activity. It has been shown 
that recombinant chimeric molecules having LACI inhibitor 
(Kunitz type) regions and the Gla domain of FXa can be 
inhibitory of the TF pathway. 
TABLE 1 
VKD proteins. 
Protein C Factor X(FX) Bone Gla protein (Osteocalcin) 
Protein S Prothrombin 
Protein Z. Factor VII 
Factor IX 
Gamma-carboxylation is required for calcium-dependent 
membrane binding. All of the proteins listed in Table 1 have 
multiple Gla-residues in a concentrated domain. The Gla 
domains of these proteins mediate interaction and the forma 
tion of multi-protein coagulation protein complexes. Mam 
malian coagulation (here collectively meaning both pro 
coagulation and anti-coagulation pathways and mechanisms) 
physiology requires that nearly complete-carboxylation of 
VKD-proteins occurs within the respective Gla domain for 
each of these proteins to be maximally functional. Notably, in 
the context of recombinant synthesis of any protein contain 
ing Gla-domains, the extent of gamma-carboxylation of 
VKD-proteins varies from one mammalian cell source to 
another, including differences between species and tissue 
within a species. 
VKD-proteins of interest with respect to production by 
single or multi gene expression systems include those in 
Table 1, particularly blood clotting factor IX, Protein C and 
chimeric hybrid vitamin K-dependent proteins. Factor IX is 
an essential blood clotting protein. Haemophilia B is a genetic 
disorder in which the production of active Factor IX is defec 
tive. It is an inherited disorder that primarily affects males, at 
US 7,888,321 B2 
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the rate of approximately 1 in 30,000. The consequent inabil 
ity to produce sufficient active Factor IX can lead to profuse 
bleeding, both internally and externally, either spontaneously 
or from relatively minor injuries. 
In spite of techniques available to amplify recombinant 5 
synthesis of VKD proteins such as Protein C and Factor IX, 
biologically functional recombinant versions of these pro 
teins are difficult to produce and are made typically at levels 
less than about 0.1 grams per liter per 24hours in recombinant 
cell culture media (Grinnell, B. W., et al., in Protein C and 10 
Related Anticoagulants. Bruley, D. F. and Drohan, W. N. 
(eds.), Houston, Tex.; Gulf Publishing Company, 29-63, 
1990), or less than 0.22 gm per liter per hour in the milk of 
transgenic livestock (Van Cott, K. E., et al., Genetic Analysis: 
Biomolecular Eng., 15, 155-160, 1999). The expression of 15 
high levels of FIX using a cDNA construct is difficult. How 
ever, the gldNA of FIX, at 33 kbp, is rather large and difficult 
to manipulate, particularly when compared to the FIX cDNA, 
which is only 1.4 kbp. 
Most VKD-blood plasma proteins are also glycosylated. 20 
The extent and types of glycosylation observed is heteroge 
neous and varies considerably in all species and cell types 
within a species. Examples of the heterogeneity, structure 
function relationships of glycosylation are cited by Degen, 
Seminars in Thrombosis and Hemostasis, 18(2), 230-242, 25 
1992; Prothrombin and Other Vitamin K Proteins, Vols I and 
II, Seegers and Walz, Eds. CRC Press, Boca Raton, Fla., 
1986. 
Glycosylation is a complex post translational modification 
that occurs on many therapeutic proteins. The process of 30 
glycosylation attaches polymeric Sugar compounds to the 
backbone of a protein. These sugar-based structures impart 
not only an immunologically specific signature upon the pro 
tein, but also can change the specific level of activity that the 
protein has with relation to how long it can reside in the 35 
bloodstream of a patient, or how active the protein is in its 
basic function. All three of these facets can make or break the 
protein in its role as a therapeutic or wellness product. For 
example, genetically engineered yeast can impart glycosyla 
tion that results in an immunologically adverse signature, 40 
which can stimulate the body to make antibodies and essen 
tially reject the protein. In fact, that is part of the reason why 
yeast vaccines are effective; they easily induce an immune 
response. The mammary gland of ruminants produces a Sub 
stantial fraction of glycosylation on milk proteins which 45 
resemble the primitive Sugars found in yeast. Thus, applica 
tions that result in the long term, repeated exposure of pro 
teins containing yeast or yeast-like signatures, to human tis 
sue are intensely scrutinized with respect to the potential of 
adverse immune reactions. This structure is also apt to cause 50 
dysfunction with respect to the proteins natural activity and 
may also contribute to a shortened residence time in blood. In 
contrast, the mammary gland of pigs gives a glycosylation 
signature which more closely resembles that found in normal 
human blood proteins, helping to assure biochemical func- 55 
tion and a long circulatory half-life. 
The complex post-translational modifications of therapeu 
tic proteins, such as those discussed above that are necessary 
for physiological activities, pose a difficult obstacle to the 
production of active vitamin K dependent proteins in cells 60 
using cloned genes. Moreover, attempts to culture genetically 
altered cells to produce VKD polypeptides have produced 
uneconomically low yields and, generally, preparations of 
low specific activity. Apparently, the post-translational modi 
fication systems in the host cells could not keep pace with 65 
production of exogenously encoded protein, reducing spe 
cific activity. Therefore, cell culture production methods have 
8 
not provided the hoped for advantages for producing highly 
complex proteins reliably and economically. 
An attractive alternative is to produce these complex pro 
teins in transgenic organisms. However, it is likely that only 
mammals and perhaps birds will be able to carry out all the 
post-translational modifications necessary for their physi 
ological function. It has not been possible, as yet, to produce 
commercially viable levels of certain complex polypeptides 
from a controlled source in a highly active form with a good 
yield, and there exists a need for better methods to produce 
Such proteins. 
An interesting new class of proteins, which is likely to be 
difficult to produce in commercial quantities in cell culture 
are the genetically engineered fusion, chimeric and hybrid 
molecules which are now being developed. These proteins are 
designed and produced by combining various domains or 
regions from different natural proteins, either wild type or 
mutated, which can confer the properties of each domain or 
region to the final hybrid molecule. An example of this is 
XLACI (Girard, T. J., et al., Science 248, 1421-1424, 
1990) which is a hybrid protein made up of domains from 
factor X and lipoprotein-associated coagulation inhibitor 
(LACI). LACI appears to inhibit tissue factor (TF)-induced 
blood coagulation by forming a quaternary inhibitory com 
plex containing FXa. LACI, FVIIa and TF. XLACI 
directly inhibits the activity of the factor VIIa-TF (tissue 
factor) catalytic complex, but is not dependent on FXa. 
Gamma-carboxylation of the FX portion of the hybrid protein 
is required for inhibitory activity. In order for efficient car 
boxylation to occur at high levels, it is likely that the pro 
peptide of the recombinant VKD-protein must be properly 
matched to the endogenous carboxylase system (Stanley, T. 
B. etal, J. Biol. Chem., 274(24), 16940-16944, 1999). This is 
probably true for all VKD-polypeptides including chimeric 
ones such as XLACI. It appears that the endogenous 
carboxylase systems of any given species or tissue within that 
species, most of which are not identified or characterized, will 
differ in their compatibility to any given pro-peptide 
sequence. Also it is frequently desirable to have the pro 
peptide cleaved from the nascent VKD protein, such as a 
XLACI polypeptide, once gamma-carboxylation has 
been completed on the polypeptide’s gla domain. It is there 
fore, also important to find a propeptide sequence that will be 
efficiently cleaved within the specific species and tissue in 
which it is being recombinantly produced. These factors ren 
der it problematic to find an expression system which can 
produce desirable amounts of biologically active VKD-pro 
teins such as XLACI chimeric proteins. In spite of being 
known as a potent coagulation inhibitor since the early 1990s, 
XLACI chimeric molecules have not been made in large 
amounts in a commercially viable manner (ie., greater than 
0.1 gm per liter per 24 hours) in recombinant mammaliancell 
culture. One way to improve expression of this protein in a 
transgenic system, particularly in transgenic pigs, may be to 
substitute the FIX propeptide sequence for the FX propeptide 
sequence, such a protein would be termed 9XKI. 
New therapeutic molecules are being designed to have 
increased activity, decreased inactivation, increased half-life 
or specific activity and reduced immunogenicity and/or 
immunoreactivity to existing circulating antibodies in 
patients’ bloodstreams. This has been demonstrated in geneti 
cally engineered Factor VIII proteins (U.S. Pat. No. 5,364, 
771, U.S. Pat. No. 5,583.209, U.S. Pat. No. 5,888,974, U.S. 
Pat. No. 5,004,803, U.S. Pat. No. 5,422,260, U.S. Pat. No. 
5,451,521, U.S. Pat. No. 5,563,045). Mutations include dele 
tion of the B domain (Lind, P. et al., Eur. J. Biochem. 232, 
19-27, 1995), domain substitution or deletion, covalent link 
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age of domains, site-specific replacement of amino acids and 
mutation of certain cleavage sites. In particular, a genetically 
engineered inactivation-resistant factor VIII (IR8) has been 
developed to help in the treatment of hemophilia A (Pipe, S. 
W. and Kaufman, R. J., PNAS 94, 11851-11856, 1997). The 
introduction of specific sequences from porcine factor VIII 
can also be useful in the formation of a recombinant FVIII 
which is used to treat hemophiliacs with improved properties 
as stated above. These molecules can also be designed for 
improved expression. It is widely known that FVIII has 
restrictions in intracellular trafficking which lead to low lev 
els of secretion. Modification of the domains associated with 
intracellular interactions with immunoglobulin binding pro 
tein (Bip) or calnexin would be examples of modifications 
used to improve secretory processing efficiency (Kaufman, 
R. J. Abstract S1-8, 10" Int. Biotech. Symp., Sydney, Aus 
tralia, 25-30 August, 1996). Factor VIII g|DNA is another 
example of an extremely large and unwieldy DNA sequence 
(-110kbp), whereas the cDNA is only 7 kbp, making it much 
more manageable. 
Whey acidic protein (referred to as “WAP) is a major 
whey protein in the milk of mice, rats, rabbits and camels. The 
regulatory elements of the mouse WAP gene are entered in 
GenBank (U38816) and cloned WAP gene DNAs are avail 
able from the ATCC. The WAP promoter has been used suc 
cessfully to direct the expression of many different heterolo 
gous proteins in transgenic animals for a number a years 
(EP0264166, Bayna, E. M. and Rosen, J. M., NAR, 18(10), 
2977-2985, 1990). Lubon etal (U.S. Pat. No. 5,831,141) have 
used a long mouse WAP promoter (up to 4.2 kbp) to produce 
Protein C in transgenic animals. However, the longest rat 
WAP promoter that has been used is 949 bp (Dale, T.C., et al., 
Mol. Cell. Biol., 12(3), 905-914, 1992). 
SUMMARY 
The present invention is directed to producing transgenic 
proteins, compositions comprising transgenic proteins, trans 
genic organisms for making proteins, for modifying trans 
genic proteins in Vivo, and to addressing the previously-dis 
cussed issues, e.g., as characterized in connection with the 
above-cited references each of which is incorporated by ref 
erence generally and more specifically as such teachings 
relate to methodology for related transgenic protein produc 
tion and applications of Such proteins. 
In various embodiments of the present invention there is a 
composition for treating hemophilia B comprising a milk 
derivative containing recombinant human factor IX derived 
from a bodily fluid produced in a transgenic organism as 
described below. 
In other more specific embodiments, the present invention 
is directed to a non-human transgenic mammal containing an 
exogenous DNA molecule stably integrated in its genome. 
The exogenous DNA molecule comprises: (a) a mammary 
gland-specific gene including a promoter; (b) a Factor IX 
encoding DNA sequence that encodes the endogenous secre 
tion-signal sequence, a Factor IX pro-sequence and a Factor 
IX sequence; (c) 3' regulatory sequences from a mammary 
gland-specific gene, which sequences are operatively linked 
to said Factor IX-encoding DNA sequence; (d) the stably 
integrated exogenous DNA does not include a WAP milk 
protein gene for providing gene rescue to achieve expression 
of the Factor 1xDNA; and (e) said Factor IX is secreted into 
the milk at least 220 micrograms Factor IX per milliliter of 
milk and is not activated by the milk-environment and there 
fore useable for Factor IX therapeutic applications. 
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Other objects, features and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
detailed description and the specific examples, while indicat 
ing preferred embodiments of the invention, are given by way 
of illustration only, since various changes and modifications 
within the spirit and scope of the invention will become 
apparent to those skilled in the art from this detailed descrip 
tion. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The invention may be more completely understood in con 
sideration of the detailed description of various embodiments 
of the invention in connection with the accompanying draw 
ings, in which: 
FIG. 1 is assembly of the plasmid pWAPFIX, according to 
an example embodiment of the present invention; 
FIG. 2 is assembly of the plasmid pUCWAPFIX, according 
to another example embodiment of the present invention; and 
FIG. 3 is production of the modified plasmid puCNot1. 
according to yet another example embodiment of the present 
invention. 
FIG. 4 is the production of puCWAP6, according to yet 
another example embodiment of the present invention. 
While the invention is amenable to various modifications 
and alternative forms, specifics thereof have been shown by 
way of example in the drawings and will be described in 
detail. It should be understood, however, that the intention is 
not necessarily to limit the invention to the particular embodi 
ments described. On the contrary, the intention is to cover all 
modifications, equivalents, and alternatives falling within the 
spirit and scope of the invention as defined by the appended 
claims. 
DETAILED DESCRIPTION 
As previously mentioned, the present invention is directed 
to products and approaches for regulating the expression of a 
protein in a transgenic organism, methods for obtaining 
polypeptides from transgenic organisms, compositions com 
prising transgenically produced polypeptides, and uses 
thereof. For example, one embodiment of the present inven 
tion is directed to a non-human transgenic mammal contain 
ing an exogenous DNA molecule that is stably integrated in 
its genome. The exogenous DNA molecule includes a mam 
mary gland-specific gene, a Factor IX-encoding DNA 
sequence that performs encoding for applicable sequences, 
and 3' regulatory sequences from a mammary gland-specific 
gene. Surprisingly, in connection with the present invention, 
it has been discovered that, with the 5' and 3' regulatory 
sequences that are operatively linked to the Factor IX-encod 
ing DNA sequence with the stably integrated exogenous 
DNA not including a WAP milk protein gene for providing 
gene rescue to achieve expression of the Factor IX DNA, the 
Factor IX can be made and secreted into the milk, so that the 
Factor IX containing milk can be made suitable for Factor IX 
therapeutic applications. 
Methods for Making Transgenic Organisms 
Transgenic organisms may be produced in accordance with 
the invention as described herein using a wide variety of 
well-known techniques, such as those described in Perry, M. 
M. and Sang, H.M., Transgenic Res. 2, 125-133; Ho Hong, Y. 
et al., Transgenic Res. 7(4), 247-252, 1998; Genetic Engi 
neering Of Animals, Ed. A. Puhler, VCH Publishers, New 
York (1993) and in more detail in Volume 18 in Methods in 
Molecular Biology: Transgenesis Techniques, Eds. D. Mur 
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phy and D. A. Carter, Humana Press, Totowa, N.J. (1993); all 
of which are incorporated herein by reference in their entire 
ties, particularly as to the foregoing in parts pertinent to 
methods for making transgenic organisms that express 
polypeptides. See also for instance Lubon et al., Transfusion 
Medicine ReviewsX (2): 131-141 (1996) and Pursel, V.G., et 
al., 480 in the proceedings of 11" International Congress on 
Animal Reproduction and Artificial Insemination, Dublin, 
Ireland, 1988, which are incorporated herein by reference in 
their entirety, particularly as to the foregoing in parts perti 
nent to methods for making transgenic organisms. 
In particular, transgenic mammals, such as mice and pigs, 
that express polypeptides in accordance with certain pre 
ferred embodiments of the invention, can be produced using 
methods described in among others Manipulating The Mouse 
Embryo, Hogan et al., Cold Spring Harbor Press (1986); 
Krimpenfort et al., Bio/Technology 9: 844 et seq. (1991); 
Palmiter et al., Cell 42: 343 et seq. (1985); Genetic Manipu 
lation of the Early Mammalian Embryo, Kraemer et al., Cold 
Spring Harbor Press, Cold Spring Harbor, N.Y. (1985): Ham 
mer et al., Nature 315: 680 et seq. (1985); U.S. Pat. No. 
4,873,191 of Wagner et al. for Genetic Transformation of 
Zygotes, and U.S. Pat. No. 5,175.384 of Krimpenfort et al. for 
Transgenic Mice Depleted in Mature T-Cells and Methods for 
Making Transgenic Mice, each of which is incorporated 
herein by reference in its entirety, particularly as to the fore 
going in parts pertinent to producing transgenic mammals by 
introducing DNA or DNA:RNA constructs for polypeptide 
expression into cells or embryos. 
For example, transgenic organisms of the present invention 
can be produced by introducing into eggs, or developing 
embryos, one or more genetic constructs that engender 
expression of polypeptides as described herein. In certain 
preferred embodiments of the invention, DNAs that comprise 
cis-acting transcription controls for expressing a polypeptide 
operably linked to a region encoding the polypeptide are 
highly preferred. In other preferred embodiments a multi 
gene system directing expression of a polypeptide and con 
taining the DNA sequences coding for Such a polypeptide, are 
highly preferred. Also highly preferred in this regard are 
single and or multi-gene constructs as described herein, that 
engender expression of genetically engineered genes for 
polypeptides. Constructs that comprise operable signal 
sequences that effectuate transport of the polypeptide product 
into a targeted compartment of an organism, Such as a tissue 
or fluid, are further preferred in certain embodiments in this 
regard. Also especially preferred in this regard are constructs 
that are stably incorporated in the genome of germ line cells 
of the mature organism and inherited in normal, Mendelian 
fashion upon reproduction. One or more DNA or RNA:DNA 
hybrids or the like may be used alone or together to make 
transgenic organisms useful in the invention as described 
further below. 
Standard, as well as unusual and new techniques for mak 
ing transgenic organisms generally can be used to make trans 
genic organisms in accordance with the invention. Useful 
techniques in this regard include, but are not limited to, those 
that introduce genetic constructs by injection, infection, 
transfection—such as calcium phosphate transfection, using 
cation reagents, using sperm or sperm heads or the like— 
lipofection, liposome fusion, electroporation, and ballistic 
bombardment. Useful techniques include both those that 
involve homologous recombination, which can be employed 
to achieve targeted integration, and those that do not, such as 
those disclosed below. 
Constructs can be introduced using these and other meth 
ods into differentiated cells, such as fibroblast cells, which are 
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capable of being reprogrammed and then cloned, pluripotent 
cells, totipotent cells, germ line cells, eggs, embryos at the 
one cell stage, and embryos at several cell stages, among 
others, to make transgenic organisms of the invention. In 
these regards, among others, they may be introduced by Such 
methods into pronuclear, nuclear, cytoplasmic or other cell 
compartments or into extracellular compartments of multi 
cellular systems to make transgenic organisms of the inven 
tion. 
In a preferred method, developing embryos can be infected 
with retroviral vectors and transgenic animals can be formed 
from the infected embryos. In a particularly preferred method 
DNAs in accordance with the invention are injected into 
embryos, at the single-cell or several cell stage. In some 
particularly preferred embodiments in this regard, DNA is 
injected into the pronucleus of a one-cell embryo. In other 
preferred embodiments in this regard. DNA is injected into 
the cytoplasm of a one-cell embryo. In yet another particu 
larly preferred embodiment in this regard, DNA is injected 
into an early stage embryo containing several cells. 
The following examples are provided merely to illustrate 
the invention, and are not to be interpreted as limiting the 
scope of the invention which is described in the specification 
and appended claims. 
It is important to note that recombinant human Factor IX 
(rhFIX) and “FIX' made by a transgenic animal are here 
terms for the same species. The Short WAP-FIX-cDNA is a 
genetic construct described below and is a term for the genetic 
construction using the 2.5 kbp fragment of the mouse WAP 
promoter operably linked to the cDNA of FIX. The Long 
WAP-FIX-cDNA is a genetic construct described below and 
is a term for the genetic construction using the 4.1 kbp frag 
ment of the mouse WAP promoter operably linked to the 
cDNA of FIX. 
Example 1 
Construction and preparation of the 2.5 kbp WAP driven 
FIX-cDNA (short WAP-FIX-cDNA) construct to be used 
without gene rescue from a milk protein gene for microinjec 
tion into transgenic animals: 
Generally, for achieving single gene expression systems 
for the transgenic animals described above, several parts of 
the entire murine WAP gene, which included the 2.5 kbp of 
5'-untranslated promoter sequence and 3' untranslated 
regions (3'-UTR) were used and cloned by standard methods. 
See Campbell et al., Nucleic Acids Res. 12:8685 (1984). A 
cDNA fragment encoding human Factor IX was obtained 
such that the 3' untranslated region of the FIX cDNA was 
deleted. Using standard methods, an expression vector was 
constructed so that it contained a mouse WAP promoter, 
isolated as a 2.5 kbp EcoRI-KpnI fragment immediately 5' to 
the WAP signal sequence (the “short WAP promoter”), the 
human Factor IX cDNA (FIX-cDNA) sequence lacking a 3 
untranslated region, and a 1.6 kbp fragment of the 3' untrans 
lated region of the WAP gene. Expression vectors were ampli 
fied by bacterial transformation and purified from bacterial 
cultures using standard methods. Routine recombinant DNA 
techniques can be found, for example, in Sambrook et al., 
MOLECULAR CLONING, A LABORATORY MANUAL, 
Vol. 1-3 (Cold Spring Harbor Press 1989. 
More specifically, a chimeric 2.5 kbp WAP 5'-promoter 
Factor IX-3' WAP UTR construct was prepared, as follows: 
Step 1: Production of pWAP4 “cassette vector” 
Regulatory 5' and 3’ flanking sequences of the mouse WAP 
gene were used as a source of the mammary specific expres 
sion system (Vector containing WAP gene a gift from Lothar 
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Hennighausen, NIH). Specifically, a cassette vector contain 
ing a mouse WAP promoter, defined as a 2.5 kbp EcoRI-KpnI 
fragment (known as the “short WAP promoter) immediately 
5' to the WAP signal sequence and a 1.5 kbp fragment of the 
3'-untranslated region of the WAP gene was prepared. These 
regulatory sequences do not include coding and intragenic 
untranslated sequences (introns) of the WAP gene. The vector 
designated pWAP4 was derived from pWAPPC3 (C. Russell, 
dissertation “Improvement of Expression of Recombinant 
Human Protein C in the Milk of Transgenic Mammal Using a 
Novel Transgenic Construct. Virginia Polytechnic Institute, 
Blacksburg, Va. (December 1993)) and was developed as 
follows: Using WAPPC3 as a template, PCR primers 
WAP3'S2 (which contains a 5'KpnI site and is homologous to 
endogenous WAP right after the stop signal) and WAP3'A1, 
were used to produce a segment with KpnI and BamHI sites 
on either end. This segment was digested with KpnI/BamHI 
and ligated with 68 bp containing the 5' end of the WAP 3' 
UTRKpnI\BamHIdigested pWAPPC3 to remove the protein 
C coding region and insert an unique Kipn I cloning site. The 
ligation mixture was used to transform E. coli DH5C. cells by 
electroporation with resultant colonies grown on LB ampi 
cillin plates. Picked colonies were grown up in TBampicillin 
broth, plasmids isolated and cut with KpnI, BamHI or both 
and Subjected to gel electrophoresis. Sequencing was per 
formed using WAP3'A1 primer and judged as being correct. 
Step 2: The FIX cDNA (containing Kpn I sites located 
immediately before the start sequence and after the stop 
sequence) was generated as a PCR fragment. Fragment pro 
duction protocol is as follows: 100 ul total volume containing 
200 uM dNTPs, 0.5uM of each primer (humFIX5'KpnI and 
humFIX3'KpnI, 2.5 units Pfu polymerase and 30 ng of plas 
mid template (pMCDSFIX obtained from Prof. Darryl 
Stafford, Department of Biology, University of North Caro 
lina, Chapel Hill, N.C., USA), reaction mixture was subjected 
to 30 cycles of denaturation at 95°C. for 20 sec, annealing at 
50° C. for 1 min and elongation at 75° C. for 5 min 45 sec. 
After cycling, the reaction mixture was subjected to blunting 
with T4 DNA polymerase for 10 min, EDTA concentration 
brought up to 25 mM, heated to 65° C. for 15 min, and 
extracted with Phenol:Chloroform (1:1), precipitated with 
equal Volumes of 95% ethanol, aspirated, and resuspended in 
H.O. 
Step 3: Ligation, Transformation and Sequencing 
The plasmid designated puCFIX (See FIG. 1) containing 
the modified (Kpn I ends) FIX cDNA was produced by diges 
tion of both puC18 and the modified cDNA with Kpn I (per 
manufacturers instructions, Stratagene, La Jolla, Calif.) puri 
fication of digestion products by CHCl:Phenol (1:1) extrac 
tion, precipitation with equal volumes of 95% ethanol, aspi 
ration and Suspension in H2O. Ligation of plasmid and cDNA 
was per manufacturers instructions (Stratagene) using 125 ng 
of Kpn I digested puC18 and 125 ng of Kpn I digested 
modified cDNA. E. coli JM109 was transformed by elec 
troporation using ligation mixture and plated on LB amplicil 
lin plates. Selected colonies were grown up in TBampicillin 
broth. Plasmid preparations from these colonies were ana 
lyzed by restriction enzyme digestion (Kpn I) and gel elec 
trophoresis. The entire sense strand of the cDNA was 
sequenced and found to be correct as compared with FIXA 
sequences located in Genebank. 
Step 4: Introduction of FIX cDNA into pWAP4 “cassette 
vector” to produce pWAPFIX 
Both pWAP4 and pUCFIX (FIG. 1) were digested with 
Kpn I in separate reactions, Subjected to gel electrophoresis 
and the appropriate plasmid fragments removed from the gel 
and ligated. E. coli JM109 was transformed by electropora 
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tion using ligation mixture and plated on LB amplicillin 
plates. Selected colonies were grown up in TB amplicillin 
broth. Plasmid preparations from these colonies were ana 
lyzed by restriction enzyme digestion (Kpn I) then gel elec 
trophoresis. Clones positive for the insert were subjected to 
PCR analysis using primers FIXS1 and WAP3'A1 to deter 
mine the correctorientation of the insert. The correct plasmid 
is identified as pWAPFIX. The insert WAPFIX was removed 
from pWAPFIX by endonuclease digestion with EcoRI, gel 
purified and ligated into EcoRI digested puC18 in order to 
switch the bacterial vector from pBS to puC18. The new 
plasmid was designated puCWAPFIX (FIG. 2). 
Step 5: Preparation of Short WAP FIX-cDNA for Micro 
injection 
The short WAP-FIX-cDNA (WAPFIX) construct as 
described above that excised from puCWAPFIX by EcoRI 
endonuclease digestion was purified for microinjection as 
follows. After cleaving the construct from its vector, the solu 
tion was brought to 10 mM magnesium, 20 mM EDTA and 
0.1% SDS and then extracted with phenol/chloroform (1:1). 
DNA was precipitated from the aqueous layer with 2.5 vol 
umes of ethanol in the presence of 0.3 M sodium acetate at 
-20° C. overnight. After centrifugation, the pellet was 
washed with 70% ethanol, dried, and resuspended in sterile 
distilled water. The extracted DNA was purified by standard 
NaCl gradient ultracentrigation. DNA concentrations were 
determined by agarose gel electrophoresis by staining with 
ethidium bromide and comparing the fluorescent intensity of 
an aliquot of the DNA with the intensity of standards. 
Samples were then adjusted to 10 ug/ml and stored at -20°C., 
prior to microinjection. Unlike the examples of Clark et al., 
U.S. Pat. No. 5,714,345 and Van Cottet al., Genetic Analysis: 
Biomolecular Engineering 15 (1999) 155-160, no co-injec 
tion of a milk gene is done with the FIX containing construct. 
Thus, no other milk protein gene that could be used to per 
form “gene rescue' on the WAP5FIX construct was used; in 
addition to the buffer components, the microinjection mixture 
contained only the Short WAP-FIXcDNA construct DNA. 
Example 2 
Production of transgenic pigs that express the Short FIX 
cDNA without “gene rescue' from a milk protein gene. 
Step 1: Pig embryos are recovered from the oviduct and 
placed into a 1.5 ml microcentrifuge tube containing approxi 
mately 0.5 ml embryo transfer media (Beltsville Embryo 
Culture Medium). Embryos are centrifuged for 12 minutes at 
16,000xg RCF (13.450 RPM) in a microcentrifuge (Hermle, 
model Z231). The embryos are then removed from the 
microfuge tube with a drawn and polished Pasteur pipette and 
placed into a 35mm petridish for examination. Embryos are 
then placed into a microdrop of media (approximately 100 ul) 
in the center of the lid of a 100 mm petridish, and silicone oil 
was used to cover the microdrop and fill the lid to prevent 
media from evaporating. The petri dish lid containing the 
embryos is set onto an inverted microscope (Carl Zeiss) 
equipped with both a heated stage and Hoffman Modulation 
Contrast optics (200x final magnification). A finely drawn 
(Kopf Vertical Pipette Puller, model 720) and polished (Nar 
ishige microforge, model MF-35) micropipette is used to 
stabilize the embryos while about 1-2 picoliters of purified 
DNA solution (10 ug/ml) containing only short WAP-FIX 
cDNA genetic constructs without milk proteins for cDNA 
gene rescue was delivered to non-pronuclear one-cell or two 
cell pig embryos using another finely drawn micropipette. 
Embryos Surviving the microinjection process as judged by 
morphological observation are loaded into a polypropylene 
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tube (2 mm ID) for transfer into the recipient pig. About 40-50 
microinjected embryos are transferred into each hormonally 
synchronized Surrogate mother recipient female pig. 
Step 2: Determination of transgenic piglets born from 
microinjection of 1-cell and two-cell pig embryos. 
The gestation time of recipient female pigs is about 114 
days. About 4 to 11 piglets are born in each litter. To deter 
mine whether test animals carried the recombinant con 
structs, tissue samples were removed from transgenic animals 
and DNA isolated. DNA is isolated by digesting tissue in (50 
mM Tris-HCl, 0.15 M NaCl, 1 M Na CIO 10 mM EDTA, 
1% sodium dodecylsulfate, 1% 2-mercaptoethanol, 100 
ug/ml proteinase K, pH 8.0). 750 ul of lysate was extracted 
with 250 ul chloroform/phenol (1:1) followed by precipita 
tion with isopropanol 0.7 volumes, washed in 70% ethanol 
and dried. DNA is suspended in TE (10 mM Tris-HCl and 1 
mM EDTA pH 8.0). Swine produced after embryo transfer of 
microinjected embryos were screened by Southern analysis. 
10 ug of DNA isolated from tail tissue is digested with the 
endonuclease Pst Ian Subjected to agarose gel electrophoresis 
and transferred to a nylon membrane. The membrane is 
probed with a P labeled DNA fragment of the WAP pro 
moter consisting of the Not I to Pst I (-2.0 kbp) 5' fragment. 
Hybridization is carried out at 68°C. for 4 hours using Quick 
Hyb (Stratagene; LaJolla, Calif.). Following standard wash 
ing methods, the membrane is Subjected to autoradiography 
(-70° C.) for a period of 24 hours. Observance of a 2.0 kbp 
band indicated the presence of the transgene. To confirm the 
presence of the Factor IX cDNA, 10ug of DNA isolated from 
tail tissue is digested with the endonuclease BamHIan Sub jected to agarose gel electrophoresis and transferred to a 
nylon membrane. The membrane is probed with a Plabeled 
DNA fragment of the FIX cDNA consisting of the whole 
cDNA Kpn I to Kpn I (~1.4 kbp). Hybridization is carried out 
at 68°C. for 4 hours using Quick Hyb (Stratagene; LaJolla, 
Calif.). Following standard washing methods, the membrane 
is subjected to autoradiography (-70° C.) for a period of 24 
hours. Observance of a ~5.5 kbp band indicates the presence 
of the short WAP-FIX-cDNA transgene. 
Step 3: Collection and storage of milk from transgenic pigs 
containing short WAP-FIX-cDNA without “gene rescue' 
from a milk protein gene. 
Lactating sows are injected intramuscularly with 30-60 IU 
of oxytocin (Vedco Inc., St. Joseph, Mo.) to stimulate milk 
let-down. Letdown occurs two to five minutes after injection. 
Pigs are milked by hand during the course of this study. 
Immediately after collection the milk is diluted 1:1 with 200 
mM EDTA, pH 7.0 to solubilize the caseins and then frozen. 
Small aliquots (about one milliliter) of the milk/EDTA mix 
ture are taken and centrifuged for approximately 30 minutes 
at 16000xg at 4°C. The fat layer is separated from the diluted 
whey fraction, and the diluted whey fraction is used for all 
further assays. 
Step 4: Detection of high levels of recombinant human FIX 
in milk of transgenic pigs containing short WAP-FIX-cDNA 
without the use of "gene rescue' from a milk protein gene. 
Data from milk samples that are processed to diluted whey 
samples are interpreted multiplied by a factor of 1.9 to 
account for dilution with EDTA and subsequent removal of 
milk fat. Amounts of Factor IX in milk are measured by 
polyclonal ELISA. Briefly, Immulon II microtiter plates 
(Fisher Scientific, Pittsburgh) are coated overnight with 100 
ul/well of 1:1000 rabbit anti-human Factor IX (Dako) in 0.1 
M. NaHCO, 0.1 M NaCl, pH 9.6 at 4°C. The wells are 
washed with TBS-Tween (TBST, 25 mM Tris, 50 mM NaCl, 
0.2% Tween 20, pH 7.2), and then blocked for 30 minutes 
with TBS/0.1% BSA at room temperature. Samples and 
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human Factor IX standard derived from plasma in the TBS 
BSA dilution buffer are added in triplicate to the wells (100 
ul/well) and incubated at 37°C. for 30 minutes. The wells are 
then washed and blocked for another 10 minutes at room 
temperature. Sheep anti-human Factor 1:1000 in TBS-BSA, 
is then incubated in the wells for 30 minutes at 37° C., fol 
lowed by anti-sheep IgG/HRP (Sigma, St. Louis). Bound 
chromophore is detected with OPD substrate (Abbott, Chi 
cago) at 490 nm using an EL308 Bio-Tek Microplate reader. 
Daily expression levels of FIX are about 100-500 g/ml milk 
and this is maintained throughout 50-60 day lactation. 
Step 5: Western analysis of the high level expression of 
recombinant human FIXinmilk of transgenic pigs containing 
short WAP-FIX-cDNA without the use of “gene rescue” from 
a milk protein gene. 
Recombinant human Factor IX (rhFIX) also is examined 
using Western Blot Analysis. Daily samples of EDTA-diluted 
whey as prepared above and taken from transgenic short 
WAP-FIXcDNA pigs are electrophoresed on 8-16% SDS gels 
(Novex, San Diego). Approximately 125 ng of recombinant 
human Factor IX (as determined by polyclonal ELISA) and 
human Factor IX standard derived from plasma are loaded in 
each lane. A total of 25 ug of total protein from a pool of 
non-transgenic (NTG) whey is loaded on the gels. After elec 
trophoresis, proteins are transferred overnight to PVDF mem 
branes (Bio Rad). The membranes are washed for 30 minutes 
in TBST, blocked with TBS/0.05% Tween 20/0.5% Casein 
(TBST-Casein). The membranes are developed with rabbit 
anti-Factor IX (Dako) (1:1000 in TBST-Casein for 45 min 
utes at 37° C.), followed by anti-rabbit IgG/HRP (Sigma) 
(1:1000 in TBST-Casein for 45 minutes at 37° C.), and the 
DAB metal enhanced staining (Pierce). Molecular weight 
markers are purchased from Bio-Rad. The presence of about 
100-500 ug/ml of rhFIX in the milk of transgenic pigs con 
taining the short WAP-FIX-cDNA without benefit of the gene 
rescue by a milk protein gene is detected by the Western Blot 
Analysis. 
Example 3 
Purification of high levels of recombinant human FIX 
(rhFIX) in milk of transgenic pigs containing short WAP 
FIX-cDNA having achieved high expression of rhEIX with 
out the use of "gene rescue' from a milk protein gene. 
Recombinant human Factor IX is purified from whey 
derived from a pool consisting of milk taken from 50-60 days 
of the first lactation of a short WAP-FIX-cDNA transgenic 
pig. The first step consisted of ion exchange chromatography 
followed by metal-dependent immunoaffinity chromatogra 
phy using a monoclonal antibody designated as MAb1 H5. In 
these studies, all columns and buffers are kept at 4°C. A pool 
of daily EDTA-expanded whey samples is diluted to OD 280 
um of 5.0 with TBS, pH 7.2, then loaded at 1 cm/min on 
DEAE FF Sepharose. The column is washed with TBS, pH 
7.2, and then eluted with 0.25 MNaCl in TBS. This fraction 
is diluted 1:1 with 40 mM MgCl, in TBS to a final concen 
tration of 20 mM MgCl2 and loaded on a 1H5 MAb column. 
The column is washed with TBS containing 20 mM MgCl, 
and the product is eluted with 20 mM citrate, 0.15 M NaCl, 
pH 6.8. The product is dialyzed overnight against 10 mM 
imidazole, pH 7.2. 
Example 4 
Determination of the biological activity of immunopurified 
recombinant Human Factor IX (rhFIX) processed from milk 
of transgenic pigs containing short WAP-FIX-cDNA having 
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achieved high level expression of rhFIX without using “gene 
rescue' from a milk protein gene. 
The biological activity of the purified recombinant human 
Factor IX from a transgenic pig is measured using a one-stage 
activated partial thromboplastin clotting time assay (APTT) 
clotting assay following a protocol given by the American 
Red Cross Plasma Derivatives Laboratory (Procedure for 
Factor IX Coagulation Assay, March 1992). Briefly, each well 
of a plastic Coag-a-mate tray receives 90 ul of Factor IX 
deficient plasma plus 10ul of a Factor IX standard or sample, 
diluted with Tris/saline/BSA. The tray is then placed on an 
automated analyzer (APTT mode, 240 second activation). 
The run is started, which automatically performed the addi 
tion of 100 ul of APTT reagent and 100 ul of 0.025 M CaCl. 
Data obtained using a standard Factor IX preparation are 
fitted to the equation y-ax+b where y-clotting time and 
X-Factor IX, which is then used to determine the amount of 
Factor IX in a sample. The Standards of normal plasma ref 
erence pool (Sigma) and human Factor IX derived from 
plasma are used in the assay. Duplicates of the immunopuri 
fied recombinant human Factor IX, human Factor IX, and 
normal plasma reference pool samples are run at each dilu 
tion. The immunopurified recombinant human Factor IX had 
a specific activity of about 200-350 U/mg, which is compa 
rable to the immunopurified human Factor IX from plasma 
which had a specific activity of 200-230 U/mg, with the 
normal plasma reference pool activity being defined as 250 
U/mg. 
Example 5 
A milk derivative of a recombinant Human Factor IX 
(rhEIX) processed from milk of transgenic pigs containing 
short WAP-FIX-cDNA having high level expression of rhFIX 
achieved without using "gene rescue' from a milk gene. 
A milk derivative concentrate of recombinant human FIX 
(rhFIX) useful for oral delivery of rhFIX is made from the 
milk of a transgenic pig containing a transgene composed of 
the 2.5 kbp mouse whey acidic protein promoter (WAP), the 
cDNA encoding human FIX, and a 1.6 kbp fragment of the 3' 
UTR of WAP. The expression level is about 0.1-0.5 g/l of 
rhFIX. Greater than about 80% of the rhFIX is biologically 
active. The skim milk is treated with a chelating agent Such as 
100 mM EDTA pH 7.5 or 100 mM Sodium Citrate pH 6.5 to 
clarify the milk of casein micelles. The clarified whey is 
passed over a DEAE-Sepharose or DEAE-Cellulose chro 
matographic column and the rhFIX is adsorbed. This 
adsorbed rhFIX is selectively desorbed from the anion 
exchange columnusing 15 mM Ca"Tris-buffered-saline 150 
mM NaCl (TBS). This eluted fraction of rhFIX containing 
selected, highly biologically active fractions of rhPIX is use 
ful for oral delivery of rhPIX for therapeutic treatment of 
hemophilia B patients is passed through a 0.2 micron filter top 
remove bacterial contamination and then lyophilized to a 
powder. The rhFIX in the DEAE-column eluate has a com 
position that is volume reduced and concentrated by 25 to 
50-fold over that of starting skim milk. 
Example 6 
A therapeutic application achieving oral delivery of the 
recombinant Human Factor IX (rhFIX) using a milk deriva 
tive made from the milk of transgenic pigs containing short 
WAP-FIX-cDNA having high level expression of rhFIX 
achieved without using "gene rescue' from a milk protein 
gene. 
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The lyophilized powder of example 5 is reconstituted with 
aqueous containing ordinary bovine milk cream Such as to 
restore the volume to 25 to 50-fold concentrate over that of the 
original whey. The mixture is fed to hemophilia type B mice 
shortly after their first meal post sleep where less than 1 ml is 
fed to each mouse. The bleeding time by measured tail inci 
sion is measured 12 hours later. The corrected bleeding time 
is 5-7 minutes as compared to 11 minutes for a control hemo 
philiac mouse who was not fed the rhFIX milk concentrate 
and 5 minutes for a normal mouse with normal hemostasis. 
Example 7 
A therapeutic application achieving oral immunotoleriza 
tion of recombinant Human Factor IX (rhFIX) derived from 
Chinese Hamster Ovary cells using a milk derivative contain 
ing rhFIX made from milk of transgenic pigs containing short 
WAP-FIX-cDNA having high level expression of rhFIX 
achieved without using "gene rescue' from a milk protein 
gene. 
Mice are fed the reconstituted mixture from example 6 
everyday consecutively for one month and after this month, 
they are sensitized with complete Freund's adjuvant and 
recombinant human Factor IX. After 12 days, blood samples 
from these mice do not respond with the presence of anti 
human FIX antibodies and also does not respond with T-cells 
which are activated by the presence of recombinant FIX 
derived from Chinese Hamster ovary cells. Control mice that 
have not been fed the mixture from example 12 are sensitized 
with the same adjuvant and human FIX mixture. After 12-14 
days the blood of these human FIX sensitized control mice 
exhibit a strong immunological response consisting of both 
anti-human FIX antibodies and T-cells that are activated by 
the presence of human FIX. 
Example 8 
A therapeutic application achieving oral immunotoleriza 
tion of recombinant Human Factor IX (rhFIX) using a milk 
derivative having the same rhFIX that is made from milk of 
transgenic pigs containing short WAP-FIX-cDNA having 
high level expression of rhFIX achieved without using “gene 
rescue' from a milk protein gene. 
Mice are fed the reconstituted mixture from example 6 
everyday consecutively for one month and after this month, 
they are sensitized with complete Freund's adjuvant and 
recombinant human Factor IX. After 12 days, blood samples 
from these mice do not respond with the presence of anti 
human FIX antibodies and also do not respond with T-cells 
which are activated by the presence of recombinant FIX 
derived from the milk of transgenic pigs. Control mice that 
have not been fed the mixture from example 12 are sensitized 
with the same adjuvant and human FIX mixture. After 12-14 
days the blood of these human FIX sensitized control mice 
exhibit a strong immunological response consisting of both 
anti-human FIX antibodies and T-cells that are activated by 
the presence of human FIX. 
Example 9 
A therapeutic application achieving oral immunotoleriza 
tion of Human Factor IX derived from plasma using a milk 
derivative containing rhFIX made from milk of transgenic 
pigs containing short WAP-FIX-cINA having high level 
expression of rhFIX achieved without using “gene rescue' 
from a milk protein gene. 
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Mice are fed the reconstituted mixture from example 6 
everyday consecutively for one month and after this month, 
they are sensitized with complete Freund's adjuvant and 
recombinant human Factor IX. After 12 days, blood samples 
from these mice do not respond with the presence of anti 
human FIX antibodies and also do not respond with T-cells 
which are activated by the presence of human FIX. Control 
mice that have not been fed the mixture from example 12 are 
sensitized with the same adjuvant and human FIX mixture. 
After 12-14 days the blood of these human FIX sensitized 
control mice exhibit a strong immunological response con 
sisting of both anti-human FIX antibodies and T-cells that are 
activated by the presence of human FIX. 
Example 10 
Construction and preparation of the 4.1 kb WAP driven 
FIX-cDNA (long WAP-FIX-cDNA) construct 
for microinjection into embryos to make transgenic ani 
mals having high level expression of FIX achieved without 
using "gene rescue” from a milk gene. 
Step 1: Generally, the entire murine WAP gene was cloned 
by standard methods, as described above in Example 1, and 
the regulatory 5' and 3' UTR-flanking sequences of the mouse 
WAP gene were used for mammary specific expression (Gift 
from Lothar Hennighausen NIH). Specifically, a cassette vec 
tor (pUCWAP6) containing a “long WAP promoter, defined 
as a 4.1 kbp Not I-Kpn I fragment immediately 5' to the WAP 
signal sequence and a 1.6 kbp fragment of the 3' untranslated 
region of the WAP gene was prepared. These regulatory 
sequences do not include coding and intragenic untranslated 
sequences (introns) of the mWAP gene. The development of 
pUCWAP6 was as follows: The puC18 vector (Invitrogen) 
was cut with the enzymes EcoRI and HindIII to remove the 
multiple cloning site of the vector, blunted with exonuclease 
and ligated with Not I linkers. The plasmid was then cut with 
Not I and ligated. Ligation mixture was used to transform E. 
coli DH5C. cells on LB ampicillin plates, picked colonies 
were grown in TB ampicillin broth, plasmids were isolated 
and cut with Not I then subjected to gel electrophoresis. 
Plasmid was judged to be correct and designated as puCNotI 
(See FIG. 3). The vector pWAP4 (described above) was 
digested with EcoRI and the fragment containing the WAP 
5'-2.5 kbp promoter and 3'-UTR genetic elements were sepa 
rated by gel electrophoresis and purified. The ends of the 
fragment were modified by blunting with exonuclease and 
Not I linkers were ligated on. The fragment was cut with Not 
I and ligated into the Not I restriction site of pUCNotI then 
used to transform E. coli DH5C. cells on ampicillin plates. 
Picked colonies were grown in TB ampicillin broth. The 
Isolated plasmid was verified to be correct by Not I digestion 
with the plasmid being designated puCWAP5. The puC 
WAP5 plasmid was subjected to Kpn I digestion and a partial 
Not I digestion producing a fragment that contained the puC 
NotI vector sequence flanked by the mWAP 3'-UTR. This 
fragment was ligated with the 4.1 kb 5’-WAP promoter pro 
duced from digestion of p227.6 (gift from American Red 
Cross) with NotI, KipnI and HindIII. The ligation mixture was 
then used to transform E. coli JM109 cells that were grown on 
LBampicillin plates picked colonies were grown in TBampi 
cillin broth, plasmids isolated were cut with Not I, and NotI/ 
KpnI and judged to be correct. The plasmid was then desig 
nated puCWAP6 (See FIG. 4). 
Step 2: Production of puCWAP6FIX 
The plasmid puCWAP6FIX was produced by digestion of 
pUCWAPFIX with Kpn I and isolating the FIX cDNA by gel 
electrophoresis. This fragment was purified using a gel 
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extraction kit (Qiagen; Valencia, Calif.) and inserted into the 
KpnI site of pUCWAP6 after Kipn I digestion and both frag 
ments were then Subjected to ligation. The ligation mixture 
was then used to transform E. coli JM109 cells that were then 
plated on LBampicillin plates. Picked colonies were grown in 
TB amplicillin broth and plasmids were isolated. Isolated 
plasmids were digested with Nsi I to verify orientation of the 
cDNA insert. Plasmids that contained the insert in the correct 
orientation were designated puCWAP6FIX. After insert con 
firmation, large scale purification was undertaken, according 
to methods well known in the art. This is termed the “long 
WAP-FIX-cDNA. 
Step 3: Preparation of Long WAP-FIX-cDNA for Micro 
injection 
The Long WAP-FIX-cDNA constructed as described in the 
above in steps was excised from puCWAP6FIX by Not I 
endonuclease digestion and purified for microinjection as 
follows. After cleaving a WAP6FIX from its vector, DNA was 
purified by standard NaCl gradient ultracentrigation. DNA 
concentrations were determined by agarose gel electrophore 
sis by staining with ethidium bromide and comparing the 
fluorescent intensity of an aliquot of the DNA with the inten 
sity of standards. Samples were then adjusted to 10 ug/ml and 
stored at -20° C., prior to microinjection. No other milk 
protein gene that could be used to perform gene rescue for this 
Long WAP-FIXcDNA construct was used; in addition to the 
buffer components, the microinjection mixture contained 
only the Long WAP-FIXcDNA construct DNA. 
Example 11 
Production of Long WAP-FIX-cDNA transgenic micehav 
ing high level expression of rhEIX achieved without using 
'gene rescue' from a milk gene. 
Step 1: Transgenic mice were produced essentially as 
described by Hogan et al., Manipulating the Mouse Embryo, 
Cold Spring Harbor Press, (1986), which is hereby incorpo 
rated by reference. That is, glass needles for micro-injection 
were prepared using a micropipet puller and microforge. 
Injections were performed using a Nikon microscope having 
Hoffman Modulation Contrast optics, with Narashigi micro 
manipulators and a pico-injector driven by N2 (Narashigi). 
Fertilized mouse embryos were surgically removed from ovi 
ducts of superovulated female CD-1 mice and placed into M2 
medium. Cumulus cells were removed from the embryos with 
hyaluronidase at 300 ug/ml. The embryos were then rinsed in 
new M2 medium, and stored at 37 degrees centigrade prior to 
injection. Stock Solutions containing about 5 g/ml of the 
above described DNA were prepared and microinjected into 
non-pronuclear mouse embryos. After injecting the DNA, 
embryos were implanted into avertin-anesthesized CD-1 
recipient females made pseudo-pregnant by mating with 
vasectomized males. About 25-30 microinjected mouse 
embryos per recipient were transferred into pseudopregnant 
females. 
Step 2: DNA was isolated by digesting tissue in (50 mM 
Tris-HCl, 0.15 M NaCl, 1 M NaClO 10 mM EDTA, 1% 
sodium dodecylsulfate, 1% 2-mercaptoethanol, 100 ug/ml 
proteinase K. pH 8.0). 750 ul of lysate was extracted with 250 
ul chloroform/phenol (1:1) followed by precipitation with 
isopropanol 0.7 volumes, washed in 70% ethanol and dried. 
DNA was suspended in TE (10 mM Tris-HCl and 1 mM 
EDTA pH 8.0). Mice produced after embryo transfer of 
microinjected embryos were screened by Southern analysis. 
To confirm the presence of the Factor IX cDNA. 10 ug of 
DNA isolated from tail tissue was digested with the endonu 
clease BamHIan Subjected to agarose gel electrophoresis and 
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transferred to a nylon membrane. The membrane was probed 
with a Plabeled DNA fragment of the FIXcDNA consisting 
of the whole cDNA Kpn I to Kpn I (~1.4 kbp). Hybridization 
was carried out at 68°C. for 4 hours using Quick Hyb (Strat 
agene; LaJolla, Calif.). Following standard washing methods, 
the membrane was subjected to autoradiography (-70°C.) for 
a period of 24 hours. Observance of a ~7.1 kbp band indicated 
the presence of the whole transgene. 
Example 12 
Western Analysis of high level expression of recombinant 
human FIX in milk of transgenic mice containing long WAP 
FIX-cDNA achieved without using gene rescue from a milk 
protein gene. 
Recombinant human Factor IX from the milk of transgenic 
mice having the long WAP-FIX-cDNA (without gene rescue 
from a milk protein gene) was examined using Western analy 
sis. Daily samples of EDTA-diluted whey as prepared above 
and taken from transgenic short WAP-FIXcDNA pigs were 
electrophoresed on 8-16% SDS gels (Novex, San Diego). 
Approximately 125 ng of recombinant human Factor IX (as 
determined by polyclonal ELISA) and human Factor IX stan 
dard derived from plasma were loaded in each lane. A total of 
25 ug of total protein from a pool of non-transgenic (NTG) 
whey was loaded on the gels. After electrophoresis, proteins 
were transferred overnight to PVDF membranes (Bio Rad). 
The membranes were washed for 30 minutes in TBST, 
blocked with TBS/0.05% Tween 20/0.5% Casein (TBST 
Casein). The membranes were developed with rabbit anti 
Factor IX (Dako) (1:1000 in TBSTCasein for 45 minutes at 
37° C), followed by anti-rabbit IgG/HRP (Sigma) (1:1000 in 
TBST-Casein for 45 minutes at 37° C.), and the DAB metal 
enhanced staining (Pierce). Molecular weight markers were 
purchased from Bio Rad. Western analyses revealed the pres 
ence of three Sub-populations of recombinant human Factor 
IX in transgenic mouse derived samples: the major popula 
tion migrated at a M, of about 60-65 kDa, which is a slightly 
lower M, than human Factor IX, and minor sub-populations 
migrated at about 40-45 kDa, and at about 25 kDa. Plasma 
human Factor IX also possessed a subpopulation at about 
45-50 kDa. The transgenic mouse milk samples were esti 
mated to contain about 1 to 2 g/l of rhFIX. 
Example 13 
Production of transgenic pigs that express the long WAP 
FIX-cDNA at very high levels achieved without using “gene 
rescue' from a milk protein gene. 
Step 1: Pig embryos were recovered from the oviduct, and 
were placed into a 1.5 ml microcentrifuge tube containing 
approximately 0.5 ml embryo transfer media (Beltsville 
Embryo Culture Medium). Embryos were centrifuged for 12 
minutes at 16,000xg RCF (13.450 RPM) in a microcentrifuge 
(Hermle, model Z231). The embryos were then removed 
from the microcentrifuge tube with a drawn and polished 
Pasteur pipette and placed into a 35 mm petridish for exami 
nation. Embryos were then placed into a microdrop of media 
(approximately 100 ul) in the center of the lid of a 100 mm 
petri dish, and silicone oil was used to cover the microdrop 
and fill the lid to prevent media from evaporating. The petri 
dish lid containing the embryos was set onto an inverted 
microscope (Carl Zeiss) equipped with both a heated Stage 
and Hoffman Modulation Contrast optics (200x final magni 
fication). A finely drawn (Kopf Vertical Pipette Puller, model 
720) and polished (Narishige microforge, model MF-35) 
micropipette was used to stabilize the embryos while about 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
22 
1-2 picoliters of stock solution containing about 10 g/ml of 
the above described DNA was microinjected into the non 
pronuclear stage pig embryos using another finely drawn 
micropipette. Embryos Surviving the microinjection process 
as judged by morphological observation were loaded into a 
polypropylene tube (2 nun ID) for transfer into the recipient 
pig. About 40-50 microinjected embryos were transferred 
into each hormonally synchronized Surrogate mother recipi 
ent female pig. 
Step 2: Determination of transgenic piglets born from 
microinjection of pig embryos. 
DNA was isolated by digesting tissue in (50 mM Tris-HCl, 
0.15 M NaCl, I M Na CIO 10 mM EDTA, 1% sodium 
dodecylsulfate, 1% 2-mercaptoethanol, 100 ug/ml proteinase 
K, pH 8.0). 750 ul of lysate was extracted with 250 ulchlo 
roform/phenol (1:1) followed by precipitation with isopro 
panol 0.7 volumes, washed in 70% ethanol and dried. DNA 
was suspended in TE (10 mM Tris-HCl and 1 mM EDTA pH 
8.0). Pigs produced after embryo transfer of microinjected 
embryos were screened by Southern analysis. To confirm the 
presence of the Factor IX clNA. 10 ug DNA isolated from 
tail tissue was digested with the endonuclease BamHI an 
Subjected to agarose gel electrophoresis and transferred to a 
nylon membrane. The membrane was probed with a P 
labeled DNA fragment of the FIX clNA consisting of the 
whole cDNA Kpn I to Kpn I (~1.4 kbp). Hybridization was 
carried out at 68°C. for 4 hours using Quick Hyb (Stratagene: 
LaJolla, Calif.). Following standard washing methods, the 
membrane was subjected to autoradiography (-70° C.) for a 
period of 24 hours. Observance of a ~7.1 kbp band indicated 
the presence of the entire long WAP-FIX-cINA transgene. 
Step 3: Collection and storage of milk from transgenic pigs 
containing Long WAP-FIX-cDNA without using “gene res 
cue' by a milk protein gene. 
Lactating sows were injected intramuscularly with 30-60 
IU of oxytocin (Vedco Inc., St. Joseph, Mo.) to stimulate milk 
let-down. Letdown occurred two to five minutes after injec 
tion. Pigs were milked by hand during the course of this study. 
Immediately after collection the milk was diluted 1:1 with 
200 mM EDTA, pH 7.0 to solubilize the caseins and then 
frozen. Small aliquots (about one milliliter) of the milk/ 
EDTA mixture were taken and centrifuged for approximately 
30 minutes at 16000xg at 4°C. The fat layer was separated 
from the diluted whey fraction, and the diluted whey fraction 
was used for all further assays. 
Step 4: Detection of recombinant human fix in milk of 
transgenic pigs containing Long WAP-FIX-cINA without 
using "gene rescue' by a milk protein gene. 
Data from milk samples that were processed to diluted 
whey samples were adjusted by a factor of 1.9 to account for 
dilution with EDTA and subsequent removal of milk fat. 
Amounts of Factor IX in milk were measured by polyclonal 
ELISA. Briefly, Immulon II microtiter plates (Fisher Scien 
tific, Pittsburgh) were coated overnight with 100 ul/well of 
1:1000 rabbit anti-human Factor IX (Dako) in 0.1 M 
NaHCO, 0.1 MNaCl, pH 9.6 at 4°C. The wells were washed 
with TBS-Tween (TBST, 25 mM Tris, 50 mM NaCl, 0.2% 
Tween 20, pH 7.2), and then blocked for 30 minutes with 
TBS/0.1% BSA at room temperature. Samples and human 
Factor IX standard derived from plasma in the TBS-BSA 
dilution buffer were added in triplicate to the wells (100 
ul/well) and incubated at 37° C. for 30 minutes. The wells 
were thenwashed and blocked for another 10 minutes at room 
temperature. Sheep anti-human Factor IX 1:1000 in TBS 
BSA, was then incubated in the wells for 30 minutes at 37°C., 
followed by anti-sheep IgG/HRP (Sigma, St. Louis). Bound 
chromophore was detected with OPD substrate (Abbott, Chi 
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cago) at 490 nm using an EL308 Bio-Tek Microplate reader. 
Daily expression levels of about 2000-5000 ug/ml milk were 
maintained throughout 50-60 day lactation. 
Step 5: Western analysis of high level expression of recom 
binant human FIX (rhFIX) in milk of transgenic pigs contain 
ing long WAP-FIX-cDNA without using “gene rescue' by a 
milk protein gene. 
Recombinant human Factor IX also was examined using 
Western analysis. Daily samples of EDTA-diluted whey as 
prepared above and taken from transgenic Long WAP-FIX 
cDNA pigs were electrophoresed on 8-16% SDS gels 
(Novex, San Diego). Approximately 125 ng of recombinant 
human Factor IX (as determined by polyclonal ELISA) and 
human Factor IX standard derived from plasma were loaded 
in each lane. A total of 25 ug of total protein from a pool of 
non-transgenic (NTG) whey was loaded on the gels. After 
electrophoresis, proteins were transferred overnight to PVDF 
membranes (Bio Rad). The membranes were washed for 30 
minutes in TBST, blocked with TBS/0.05% Tween 20/0.5% 
Casein (TBST-Casein). The membranes were developed with 
rabbit anti-Factor IX (Dako) (1:1000 in TBST-Casein for 45 
minutes at 37°C.), followed by anti-rabbit IgG/HRP (Sigma) 
(1:1000 in TBST-Casein for 45 minutes at 37° C.), and the 
DAB metal enhanced staining (Pierce). Molecular weight 
markers were purchased from Bio Rad. Western analyses 
revealed the presence of three sub-populations of recombi 
nant human Factor IX: the major population migrated at a M. 
of about 60-65 kDa, which is a slightly lower M, than human 
Factor IX, and minor Sub-populations migrated at about 
40-45 kDa, and at about 25 kDa. Plasma human Factor IX 
also possessed a subpopulation at about 45-50 kDa. The con 
centration of rhFIX in milk was estimated to be about 2 g/l or 
O. 
Example 14 
Purification of recombinant human FIX in milk of trans 
genic pigs containing Long WAP-FIX-cDNA having high 
level expression of FIX achieved without using “gene rescue' 
from a milk gene. 
Recombinant human Factor IX (rhFIX) was purified from 
whey derived from a pool consisting of milk taken from 50-60 
days of the first lactation of a Long WAP-FIX-cDNA trans 
genic pig. The first step consisted of DEAE exchange chro 
matography, followed by hydrophobic interaction chroma 
tography, followed by chromatographic adsorption onto Q-Sepharoseanion exchange matrix by Ca"-specific elution. 
In these studies, all columns and buffers were kept at 4°C. A 
pool of daily EDTA-expanded whey samples was diluted to 
OD 280 nm of 5.0 with TBS, pH 7.2, then loaded at 1 cm/min 
on DEAEFF Sepharose. The column was washed with TBS, 
pH 7.2, and then eluted with 0.25 MNaCl in TBS. The rhFIX 
was eluted from the DEAE-Sepharose using 300 mMNaCl in 
TBS. This rhFIX containing eluate was dialyzed to TBS and 
loaded onto Q-Sepharose. The rhFIX was eluted from the Q-Sepharose column using 15 mM CaCl (Ca") in TBS. The 
rhFIX containing eluate from the Q-Sepharose eluate was 
rendered 1 M NaCl. The rhFIX passes through the Butyl 
column unabsorbed. The unabsorbed material from the 
Butyl-Sepharose column containing the rhFIX is dialyzed 
against TBS to remove the majority of casein milk protein 
contaminants. The dialyzed rhFIX containing fraction in TBS 
is adsorbed to Q-Sephrose and eluted in a sequence of 5 mM 
Ca", 10 mM Ca", 15 mM Ca", and 2 M NaCl in TBS 
buffers. The chromatographic procedure isolated in these 
fractions contained rhFIX to about 80% or higher purity as judged by silver-stained SDS-PAGE. 
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Example 15 
Determination of the biological activity of purified rhFIX 
processed from milk of transgenic pigs containing Long 
WAP-FIX-cDNA having high level expression of FIX 
achieved without using "gene rescue' from a milk protein 
gene. 
The biological activity of the recombinant human Factor 
IX purified from the milk of Long WAP-FIX-cDNA pigs 
described in Example 14 is measured using a one-stage acti 
vated partial thromboplastin clotting time assay (APTT) clot 
ting assay following a protocol given by the American Red 
Cross Plasma Derivatives Laboratory (Procedure for Factor 
IX Coagulation Assay, March 1992). Briefly, each well of a 
plastic Coag-a-mate tray received 90 ul of Factor IX-deficient 
plasma plus 10 ul of a Factor IX standard or sample, diluted 
with Tris/saline/BSA. The tray was then placed on an auto 
mated analyzer (APTT mode, 240 second activation). The run 
is started, which automatically performed the addition of 100 
ul of APTT reagent and 100 ul of 0.025 M CaCl. Data 
obtained using a standard Factor IX preparation are fitted to 
the equation y-ax+b where y-clotting time and X-Factor IX, 
which is then used to determine the amount of Factor IX in a 
sample. Standards of normal plasma reference pool (Sigma) 
and human Factor IX derived from plasma are used in the 
assay. Duplicates of purified recombinant human Factor IX, 
human Factor IX, and normal plasma reference pool samples 
are run at each dilution. TherhPIX in the 5 mM Ca" aspecific 
activity of about 150-250 u/mg. The rhFIX in the 10 mM Ca" 
a specific activity of about 100 u/mg or less. TheFIX in the 15 
mM Ca" a specific activity of less than about 50 u/mg. The 
rhFIX in the 2 MNaCl gives a specific activity of less than 25 
u/mg. The specific activity of the rhFIX of normal plasma 
reference pool is defined as 250 u/mg where the overall activ 
ity of the pool is 1 u/ml while containing 4 ug/ml of rhFIX. 
Example 16 
A milk derivative containing recombinant Human Factor 
IX processed from milk of transgenic pigs containing Long 
WAP-FIX-cDNA having high level expression of rhFIX 
achieved without using "gene rescue' from a milk protein 
gene. 
A milk derivative concentrate of recombinant Human FIX 
useful for oral delivery of rhFIX is made from the milk of a 
transgenic pig containing a transgene composed of the 2.5 
kbp mouse whey acidic protein promoter (WAP), the cDNA 
encoding human FIX, and a 1.6 kbp fragment of the 3'UTR of 
WAP. The expression level is about 0.1-0.5 g/l of rhFIX. 
Greater than about 80% of the rhFIX is biologically active. 
The skim milk is treated with a chelating agent such as 100 
mM EDTA pH 7.5 or 100 mM Sodium Citrate pH 6.5 to 
clarify the milk of casein micelles. The clarified whey is 
passed over a DEAE-Sepharose or DEAE-Cellulose chro 
matographic column and the rhFIX is adsorbed. This 
adsorbed rhFIX is selectively desorbed from the anion 
exchange column using 5 mM Ca" Tris-buffered-saline 150 
mM NaCl (TBS). This eluted fraction of rhFIX containing 
selected, highly biologically active fractions of rhPIX is use 
ful for oral delivery of rhFIX for therapeutic treatment of 
hemophilia B patients is pass through a 0.2 micron filter top 
remove bacterial contamination and then lyophilized to a 
powder. The rhFIX in the DEAE-column eluate has a com 
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position that is volume reduced and concentrated by 25 to 
50-fold over that of starting skim milk. 
Example 17 
A therapeutic application achieving oral delivery of the 
recombinant Human Factor IX using a milk derivative made 
from the milk of transgenic pigs containing Long WAP-FIX 
cDNA having high level expression of rhFIX achieved with 
out using "gene rescue' from a milk protein gene. 
The lyophilized powder of example 5 is reconstituted with 
aqueous containing ordinary bovine milk cream Such as to 
restore the volume to 25 to 50-fold concentrate over that of the 
original whey. The mixture is fed to hemophilia type B mice 
shortly after their first meal post sleep where less than 1 ml is 
fed to each mouse. The bleeding time by measured tail inci 
sion is measured 12 hours later. The corrected bleeding time 
is 5-7 minutes as compared to 11 minutes for a control hemo 
philiac mouse who was not fed the rhFIX milk concentrate 
and 5 minutes for a normal mouse with normal hemostasis. 
Example 18 
A therapeutic application achieving oral immunotoleriza 
tion of recombinant Human Factor IX derived from Chinese 
Hamster Ovary cells using a milk derivative containing 
recombinant FIX made from milk of transgenic pigs contain 
ing Long WAP-FIX-cDNA having high level expression of 
rhFIX achieved without using “gene rescue” from a milk 
protein gene. 
Mice are fed the reconstituted mixture from example 16 for 
everyday consecutively for one month and after this month, 
they are sensitized with complete Freund's adjuvant and 
recombinant human Factor IX. After 12 days, blood samples 
from these mice do not respond with the presence of anti 
human FIX antibodies and also does not respond with T-cells 
which are activated by the presence of recombinant FIX 
derived from Chinese Hamster ovary cells. Control mice that 
have not been fed the mixture from example 16 are sensitized 
with the same adjuvant and human FIX mixture. After 12-14 
days the blood of these human FIX sensitized control mice 
exhibit a strong immunological response consisting of both 
anti-human FIX antibodies and T-cells that are activated by 
the presence of human FIX. 
Example 19 
A therapeutic application achieving oral immunotoleriza 
tion of recombinant Human Factor IX derived from cell cul 
ture by using a milk derivative containing recombinant FIX 
made from milk of transgenic pigs containing Long WAP 
FIX-cDNA having high level expression of FIX achieved 
without using "gene rescue' from a milk gene. 
Mice are fed the reconstituted mixture from example 16 for 
everyday consecutively for one month and after this month, 
they are sensitized with complete Freund's adjuvant and 
recombinant human Factor IX derived from Chinese Hamster 
Ovary cells. After 12 days, blood samples from these mice do 
not respond with the presence of anti-human FIX antibodies 
and also does not respond with T-cells which are activated by 
the presence of recombinant FIX derived from the milk of 
transgenic pigs. Control mice that have not been fed the 
mixture from example 16 are sensitized with the same adju 
vant and rhFIX mixture. After 12-14 days the blood of these 
human FIX sensitized control mice exhibit a strong immuno 
logical response consisting of both anti-human FIX antibod 
ies and T-cells that are activated by the presence of rhFIX. 
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Example 20 
A therapeutic application achieving oral immunotoleriza 
tion of Human Factor IX derived from plasma by using a milk 
derivative containing recombinant FIX made from milk of 
transgenic pigs containing Long WAP-FIX-cDNA having 
high level expression of rhFIX achieved without using “gene 
rescue' from a milk protein gene. 
Mice are fed the reconstituted mixture from example 16 
everyday consecutively for one month and after this month, 
they are sensitized with complete Freund's adjuvant and 
recombinant human Factor IX. After 12 days, blood samples 
from these mice do not respond with the presence of anti 
human FIX antibodies and also does not respond with T-cells 
which are activated by the presence of recombinant or human 
FIX. Control mice that have not been fed the mixture from 
example 16 are sensitized with the same adjuvant and human 
FIX mixture. After 12-14 days the blood of these human FIX 
sensitized control mice exhibit a strong immunological 
response consisting of both anti-human FIX antibodies and 
T-cells that are activated by the presence of human FIX 
derived from plasma. 
What is claimed is: 
1. A milk derivative concentrate of recombinant human 
FIX useful for oral delivery to a patient comprising a biologi 
cally active Factor IX derived from milk produced by a trans 
genic pig whose genome comprises a stably integrated exog 
enous DNA molecule encoding human Factor IX, wherein 
said human Factor IX was purified and concentrated over the 
Factor IX present in said milk of said transgenic pig, and 
mixed with a pharmaceutically acceptable carrier to form said 
milk derivative concentrate comprising a dose for oral deliv 
ery from 2.5 mg/ml to 250 mg/ml of Factor IX. 
2. The milk derivative concentrate according to claim 1, 
wherein said purified human Factor IX was lyophilized to a 
powder prior to mixing with said carrier. 
3. The milk derivative concentrate according to claim 1, 
wherein said carrier is milk or a milk derivative. 
4. The milk derivative concentrate according to claim 1, 
wherein said human Factor IX was purified via chromatog 
raphy. 
5. The milk derivative concentrate according to claim 1, 
wherein said human Factor IX comprises a specific activity of 
about 150-250 U/mg in 5 mM Ca". 
6. A method of treating a patient having hemophilia B 
comprising orally administering to said patient a hemophilia 
B symptom preventing or ameliorating amount of a milk 
derivative concentrate of recombinant human FIX compris 
ing a biologically active Factor IX derived from milk pro 
duced by a transgenic pig whose genome comprises a stably 
integrated exogenous DNA molecule encoding human Factor 
IX, wherein said human Factor IX was purified and concen 
trated over the Factor IX present in said milk of said trans 
genic pig, and mixed with a pharmaceutically acceptable 
carrier to form said milk derivative concentrate, wherein said 
amount of orally administered Factor IX comprises from 2.5 
mg/ml to 250 mg/ml of Factor IX, and results in reduced 
bleeding time in said patient as compared to no administra 
tion of Factor IX to said patient, achieving atherapeutic effect 
in treating hemophilia B and achieving oral immunotoleriza 
tion of said Factor IX. 
7. The method according to claim 6, wherein said purified 
human Factor IX was lyophilized to a powderprior to mixing 
with said carrier. 
8. The method according to claim 6, wherein said carrier is 
milk or a milk derivative. 
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9. The method according to claim 6, wherein said human 
Factor IX was purified via chromatography. 
10. The method according to claim 6, wherein said human 
Factor IX comprises a specific activity of about 150-250 
U/mg in 5 mM Ca". 
11. The method according to claim 6, wherein said oral 
immunotolerization prevents the production of anti-Factor IX 
antibodies in said patient. 
12. A method of treating a patient having hemophilia B 
comprising orally administering to said patient a hemophilia 
B symptom preventing or ameliorating amount of a milk 
derivative concentrate of recombinant human FIX consisting 
essentially of a biologically active Factor IX derived from 
milk produced by a transgenic pig whose genome comprises 
a stably integrated exogenous DNA molecule encoding 
human Factor IX, wherein said human Factor IX was purified 
and concentrated over the Factor IX present in said milk of 
said transgenic pig, and mixed with a pharmaceutically 
acceptable carrier to form said milk derivative concentrate, 
wherein said amount of orally administered Factor IX com 
prises from 2.5 mg/ml to 250 mg/ml of Factor IX, and results 
in reduced bleeding time in said patient as compared to no 
administration of Factor IX to said patient, achieving a thera 
peutic effect in treating hemophilia B and achieving oral 
immunotolerization of said Factor IX. 
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13. The method according to claim 12, wherein said puri 
fied human Factor IX was lyophilized to a powder prior to 
mixing with said carrier. 
14. The method according to claim 12, wherein said carrier 
is milk or a milk derivative. 
15. The method according to claim 12, wherein said human 
Factor IX was purified via chromatography. 
16. The method according to claim 12, wherein said human 
Factor IX comprises a specific activity of about 150-250 
U/mg in 5 mM Ca". 
17. The method according to claim 12, wherein said oral 
immunotolerization prevents the production of anti-Factor IX 
antibodies in said patient. 
18. The milk derivative concentrate according to claim 1, 
wherein said human Factor IX was purified and concentrated 
by 25 to 50 fold over the Factor IX present in said milk of said 
transgenic pig. 
19. The method according to claim 6, wherein said human 
Factor IX was purified and concentrated by 25 to 50 fold over 
the Factor IX present in said milk of said transgenic pig. 
20. The method according to claim 12, wherein said human 
Factor IX was purified and concentrated by 25 to 50 fold over 
the Factor IX present in said milk of said transgenic pig. 
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